

Evaluation Warning: The document was created with Spire.Doc for Python.

_____ BILL NO. _____
INTRODUCED BY _____

BY REQUEST OF THE ECONOMIC AFFAIRS INTERIM COMMITTEE

A BILL FOR AN ACT ENTITLED: "AN ACT DESIGNATING MITRAGYNINE AND HYDROXYMITRAGYNINE
AS CONTROLLED SUBSTANCES IN MONTANA; AND AMENDING SECTION 50-32-222, MCA."

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:

Section 1. Section 50-32-222, MCA, is amended to read:

"50-32-222. Specific dangerous drugs included in Schedule I. Schedule I consists of the drugs
and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in this
section.

(1) Opiates. Unless specifically excepted or listed in another schedule, any of the following are
opiates, including isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the
existence of those isomers, esters, ethers, and salts is possible within the specific chemical designation:

(a) acetyl-alpha-methylfentanyl, also known as N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-
phenylacetamide;

(b) acetylmethadol, also known as 4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate or
methadyl acetate;

(c) allylprodine, also known as 1-methyl-4-phenyl-3-(prop-2-en-1-yl)piperidin-4-yl propanoate;

(d) alphacetylmethadol, except levo-alphacetylmethadol, also known as levo-alpha-
acetylmethadol, levomethadyl acetate, or LAAM;

(e) alphameprodine;

(f) alphamethadol;

(g) alpha-methylfentanyl, also known as N-[1-(alpha-methyl-beta-phenyl)ethyl-4-
piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine;

- 1 (h) alpha-methylthiofentanyl, also known as N-[1-methyl-2-(2-thienyl)ethyl-4-piperidiny]-N-
2 phenylpropanamide;
- 3 (i) benzethidine;
- 4 (j) betacetylmethadol;
- 5 (k) beta-hydroxyfentanyl, also known as N-[1-(2-hydroxy-2-phenethyl)-4-piperidiny]-N-
6 phenylpropanamide;
- 7 (l) beta-hydroxy-3-methylfentanyl, also known as N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-
8 piperidiny]-N-phenylpropanamide;
- 9 (m) betameprodine;
- 10 (n) betamethadol;
- 11 (o) betaprodine;
- 12 (p) brorphine;
- 13 (q) clonitazene;
- 14 (r) dextromoramide;
- 15 (s) diampromide;
- 16 (t) diethylthiambutene;
- 17 (u) difenoxin;
- 18 (v) dimenoxadol;
- 19 (w) dimepheptanol;
- 20 (x) dimethylthiambutene;
- 21 (y) dioxaphetyl butyrate;
- 22 (z) dipipanone;
- 23 (aa) ethylmethylthiambutene;
- 24 (bb) etonitazene;
- 25 (cc) etoxeridine;
- 26 (dd) fluorofentanyl;
- 27 (ee) furethidine;
- 28 (ff) hydroxymitragynine;

Evaluation Warning: The document was created with Spire.Doc for Python.

- 1 ~~(ff)~~ (gg) hydroxypethidine;
- 2 ~~(gg)~~ (hh) isotonitazene;
- 3 ~~(hh)~~ (ii) ketobemidone;
- 4 ~~(ii)~~ (jj) levomoramide;
- 5 ~~(jj)~~ (kk) levophenacymorphan;
- 6 ~~(kk)~~ (ll) 3-methylfentanyl, also known as N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-
- 7 phenylpropanamide;
- 8 ~~(ll)~~ (mm) 3-methylthiofentanyl, also known as N-[3-methyl-1-(2-thienyl)ethyl-4-piperidyl]-N-
- 9 phenylpropanamide (optical and geometric isomers only);
- 10 ~~(nn)~~ mitragynine;
- 11 ~~(mm)~~ (oo) morpheridine;
- 12 ~~(nn)~~ (pp) MPPP, also known as desmethylprodine and (1-methyl-4-phenyl-4-
- 13 propionoxypiperidine);
- 14 ~~(oo)~~ (qq) noracymethadol;
- 15 ~~(pp)~~ (rr) norlevorphanol;
- 16 ~~(qq)~~ (ss) normethadone;
- 17 ~~(rr)~~ (tt) norpipanone;
- 18 ~~(ss)~~ (uu) PEPAP, also known as (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 19 ~~(tt)~~ (vv) phenadoxone;
- 20 ~~(uu)~~ (ww) phenampromide;
- 21 ~~(vv)~~ (xx) phenomorphan;
- 22 ~~(ww)~~ (yy) phenoperidine;
- 23 ~~(xx)~~ (zz) piritramide;
- 24 ~~(yy)~~ (aaa) proheptazine;
- 25 ~~(zz)~~ (bbb) properidine;
- 26 ~~(aaa)~~ (ccc) propiram;
- 27 ~~(bbb)~~ (ddd) racemoramide;
- 28 ~~(ccc)~~ (eee) thiofentanyl, also known as N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidyl]propanamide;

Evaluation Warning: The document was created with Spire.Doc for Python.

1 ~~(ddd)~~ (fff) tilidine; and

2 ~~(eee)~~ (ggg) trimeperidine.

3 (2) Substituted fentanyls (1-phenethyl-4-N-propionylanilinopiperidine) are, unless specifically
4 excepted, listed in another schedule, approved by the United States food and drug administration, or not used
5 within legitimate and approved medical research, any material, compound, mixture, or preparation, including its
6 salts, isomers, esters, ethers, and salts of isomers, esters, or ethers whenever the existence of those salts is
7 possible, within any of the following chemical designations that are structurally related to fentanyl by one or
8 more of the following modifications:

9 (a) replacement of the phenyl portion of the phenethyl group by any monocyclic ring, whether or
10 not further substituted in or on the monocyclic ring;

11 (b) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl,
12 amino, or nitro groups;

13 (c) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo,
14 haloalkyl, amino, or nitro groups;

15 (d) replacement of the aniline ring with any aromatic monocyclic ring, whether or not further
16 substituted in or on the aromatic monocyclic ring; or

17 (e) replacement of the N-propionyl group by another acyl group.

18 (3) Opium derivatives. Unless specifically excepted or listed in another schedule, any of the
19 following are opium derivatives, including salts, isomers, and salts of isomers whenever the existence of those
20 salts, isomers, and salts of isomers is possible within the specific chemical designation:

21 (a) acetorphine;

22 (b) acetyldihydrocodeine;

23 (c) benzylmorphine;

24 (d) codeine methylbromide;

25 (e) codeine-N-oxide;

26 (f) cyprenorphine;

27 (g) desomorphine;

28 (h) dihydromorphine;

Evaluation Warning: The document was created with Spire.Doc for Python.

- 1 (i) drotebanol;
 - 2 (j) etorphine, except hydrochloride salt;
 - 3 (k) heroin;
 - 4 (l) hydromorphinol;
 - 5 (m) methyldesorphine;
 - 6 (n) methyldihydromorphine;
 - 7 (o) morphine methylbromide;
 - 8 (p) morphine methylsulfonate;
 - 9 (q) morphine-N-oxide;
 - 10 (r) myrophine;
 - 11 (s) nicocodeine;
 - 12 (t) nicomorphine;
 - 13 (u) normorphine;
 - 14 (v) pholcodine; and
 - 15 (w) thebacon.
- 16 (4) Hallucinogenic substances. Unless specifically excepted or listed in another schedule, any
- 17 material, compound, mixture, or preparation that contains any quantity of the following is a hallucinogenic
- 18 substance, including salts, isomers, and salts of isomers whenever the existence of those salts, isomers, and
- 19 salts of isomers is possible within the specific chemical designation:
- 20 (a) alpha-ethyltryptamine, also known as etryptamine, monase, alpha-ethyl-1H-indole-3-
 - 21 ethanamine, 3-(2-aminobutyl) indole, alpha-ET, and AET;
 - 22 (b) alpha-methyltryptamine, also known as AMT;
 - 23 (c) 4-bromo-2,5-dimethoxyamphetamine, also known as 4-bromo-2,5-dimethoxy-alpha-
 - 24 methylphenethylamine, and 4-bromo-2,5-DMA;
 - 25 (d) 4-bromo-2,5-dimethoxyphenethylamine, also known as 2-(4-bromo-2,5-dimethoxyphenyl)-1-
 - 26 aminoethane, alpha-desmethyl DOB, and 2C-B, Nexus;
 - 27 (e) 2,5-dimethoxyamphetamine, also known as 2,5-dimethoxy-alpha-methylphenethylamine and
 - 28 2,5-DMA;

- 1 (f) 2,5-dimethoxy-4-(N)-propylthiophenethylamine, also known as 2C-T-7;
- 2 (g) 3,4-methylenedioxyamphetamine;
- 3 (h) 2,5-dimethoxy-4-ethylamphetamine, also known as DOET;
- 4 (i) 5-methoxy-N,N-diisopropyltryptamine, also known as 5-MeO-DIPT;
- 5 (j) 5-methoxy-N,N-dimethyltryptamine, also known as 5-MeO-DMT;
- 6 (k) 4-methoxyamphetamine, also known as 4-methoxy-alpha-methylphenethylamine;
- 7 (l) 5-methoxy-3,4-methylenedioxyamphetamine;
- 8 (m) 4-methyl-2,5-dimethoxyamphetamine, also known as 4-methyl-2,5-dimethoxy-alpha-
- 9 methylphenethylamine, DOM, and STP;
- 10 (n) 3,4-methylenedioxymethamphetamine, also known as MDMA;
- 11 (o) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-alpha-methyl-
- 12 3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, and MDEA;
- 13 (p) N-hydroxy-3,4-methylenedioxyamphetamine, also known as N-hydroxy-alpha-methyl-
- 14 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA;
- 15 (q) 3,4,5-trimethoxyamphetamine;
- 16 (r) bufotenine, also known as 3-(beta-dimethylaminoethyl)-5-hydroxyindole, 3-(2-
- 17 dimethylaminoethyl)-5-indolol, N,N-dimethylserotonin, 5-hydroxy-N,N-dimethyltryptamine, and mappine;
- 18 (s) diethyltryptamine, also known as N,N-diethyltryptamine and DET;
- 19 (t) dimethyltryptamine, also known as DMT;
- 20 (u) hashish;
- 21 (v) ibogaine, also known as 7-ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-
- 22 pyrido[1', 2':1,2] azepine[5,4-b]indole and tabernanthe iboga;
- 23 (w) lysergic acid diethylamide, also known as LSD;
- 24 (x) marijuana;
- 25 (y) mescaline;
- 26 (z) parahexyl, also known as 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
- 27 dibenzo[b,d]pyran and synhexyl;
- 28 (aa) peyote, meaning all parts of the plant presently classified botanically as lophophora williamsii

Evaluation Warning: The document was created with Spire.Doc for Python.

- 1 lemaire, whether growing or not; the seed of the plant; any extract from any part of the plant; and every
2 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed, or extracts;
- 3 (bb) N-ethyl-3-piperidyl benzilate;
- 4 (cc) N-methyl-3-piperidyl benzilate;
- 5 (dd) psilocybin;
- 6 (ee) psilocyn, also known as psilocin;
- 7 (ff) tetrahydrocannabinols, neutral compounds, and their corresponding acids, including synthetic
8 equivalents of the substances contained in the plant or in the resinous extractives of cannabis, or synthetic
9 substances, derivatives, and their isomers with similar chemical structure and pharmacological activity, such as
10 those listed in subsections (4)(ff)(i) through (4)(ff)(iii). Because nomenclature of these substances is not
11 internationally standardized, compounds of these structures, regardless of numerical designation of atomic
12 positions covered, are included in the category as follows:
- 13 (i) delta 9 (delta 1) cis or trans tetrahydrocannabinol and its optical isomers;
- 14 (ii) delta 8 (delta 6) cis or trans tetrahydrocannabinol and its optical isomers; and
- 15 (iii) delta 6a, 10a (delta 3,4) cis or trans tetrahydrocannabinol and its optical isomers.
- 16 (gg) ethylamine analog of phencyclidine, also known as N-ethyl-1-phenylcyclohexylamine, (1-
17 phenylcyclohexyl)ethylamine, N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, and PCE;
- 18 (hh) pyrrolidine analog of phencyclidine, also known as 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy,
19 and PHP;
- 20 (ii) thiophene analog of phencyclidine, also known as 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-
21 thienyl analog of phencyclidine, TCP, and TCP;
- 22 (jj) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, also known as TCPy;
- 23 (kk) synthetic cannabinoids, including:
- 24 (i) unless specifically excepted or listed in another schedule, any chemical compound chemically
25 synthesized from or structurally similar to any material, compound, mixture, or preparation that contains any
26 quantity of a synthetic cannabinoid found in any of the following chemical groups, or any of those groups that
27 contain synthetic cannabinoid salts, isomers, or salts of isomers, whenever the existence of those salts,
28 isomers, or salts of isomers is possible within the specific chemical designation, including all synthetic

1 cannabinoid chemical analogs in the following groups:

2 (A) naphthoylindoles, whether or not substituted in the indole ring to any extent or the naphthyl ring
3 to any extent;

4 (B) naphthylmethylinindoles, whether or not substituted in the indole ring to any extent or the
5 naphthyl ring to any extent;

6 (C) naphthoylpyrroles, whether or not substituted in the pyrrole ring to any extent or the naphthyl
7 ring to any extent;

8 (D) naphthylmethylinindenes, whether or not substituted in the indene ring to any extent or the
9 naphthyl ring to any extent;

10 (E) acetylindoles, whether or not substituted in the indole ring to any extent or the acetyl group to
11 any extent;

12 (F) cyclohexylphenols, whether or not substituted in the cyclohexyl ring to any extent or the phenyl
13 ring to any extent;

14 (G) dibenzopyrans, whether or not substituted in the cyclohexyl ring to any extent or the phenyl ring
15 to any extent; and

16 (H) benzoylindoles, whether or not substituted in the indole ring to any extent or the phenyl ring to
17 any extent;

18 (ii) any compound that has been demonstrated to have agonist binding activity at one or more
19 cannabinoid receptors or is a chemical analog or isomer of a compound that has been demonstrated to have
20 agonist binding activity at one or more cannabinoid receptors;

21 (iii) 1-pentyl-3-(1-naphthoyl)indole (also known as JWH-018);

22 (iv) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
23 tetrahydrobenzo[c]chromen-1-ol (also known as HU-210 or 1,1-dimethylheptyl-11-hydroxy-delta8-
24 tetrahydrocannabinol);

25 (v) 2-(3-hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol (also known as CP-47,497) and the
26 dimethylhexyl, dimethyloctyl, and dimethylnonyl homologues of CP-47,497;

27 (vi) 1-butyl-3-(1-naphthoyl)indole (also known as JWH-073);

28 (vii) 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl) indole (also known as JWH-200);

Evaluation Warning: The document was created with Spire.Doc for Python.

- 1 (viii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (also known as JWH-250);
- 2 (ix) 1-hexyl-3-(1-naphthoyl)indole (also known as JWH-019);
- 3 (x) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (also known as JWH-398);
- 4 (xi) JWH-081: 1-pentyl-3-(4-methoxy-1-naphthoyl)indole, also known as 4-methoxynaphthalen-1-yl-
- 5 (1-pentylindol-3-yl)methanone;
- 6 (xii) the following substances, except where contained in cannabis or cannabis resin, namely
- 7 tetrahydro derivatives of cannabinal and 3-alkyl homologues of cannabinal or of its tetrahydro derivatives:
- 8 (A) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
- 9 naphthalenylmethanone (also known as WIN-55,212-2);
- 10 (B) 3-dimethylheptyl-11-hydroxyhexahydrocannabinol (also known as HU-243); or
- 11 (C) [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-
- 12 yl]acetate;
- 13 (II) *Salvia divinorum*, also known as salvinorin A (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-
- 14 (3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic acid methyl ester;
- 15 (mm) substituted cathinones, including any compound, except bupropion or compounds listed in
- 16 another schedule, in an administrative rule regulating controlled substances, or approved for use by the United
- 17 States food and drug administration, that is structurally derived from 2-amino-1-phenyl-1-propanone by
- 18 modification in any of the following ways:
- 19 (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl,
- 20 hydroxyl, or halide substituents, whether or not further substituted in the phenyl ring by one or more other
- 21 univalent substituents;
- 22 (ii) by substitution at the 3-position with an alkyl substituent;
- 23 (iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen
- 24 atom in a cyclic structure; and
- 25 (iv) any lengthening of the propanone chain between carbons 1 and 2 to any extent with alkyl
- 26 groups, whether further substituted or not;
- 27 (nn) substituted amphetamines, including any compound, except compounds listed in another
- 28 schedule, in an administrative rule regulating controlled substances, or approved for use by the United States

Evaluation Warning: The document was created with Spire.Doc for Python.

1 food and drug administration, that is structurally derived from 1-phenyl-2-aminopropane by modification in any
2 of the following ways:

3 (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl, or
4 halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent
5 substituents;

6 (ii) by substitution at the 3-position with an alkyl substituent;

7 (iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen
8 atom in a cyclic structure; and

9 (iv) any lengthening of the propane chain between carbons 1 and 2 to any extent with alkyl groups,
10 whether further substituted or not.

11 (5) (a) For the purposes of subsection (4), the term "isomer" includes the optical, positional, and
12 geometric isomers.

13 (b) Subsection (4)(kk) does not apply to synthetic cannabinoids approved by the United States

14 food and drug administration and obtained by a lawful prescription through a licensed pharmacy. The
15 department of public health and human services shall adopt a rule listing the approved cannabinoids and shall
16 update the rule as necessary to keep the list current.

17 (6) Depressants. Unless specifically excepted or listed in another schedule, any material,
18 compound, mixture, or preparation that contains any quantity of the following substances is a depressant
19 having a depressant effect on the central nervous system, including salts, isomers, and salts of isomers
20 whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical
21 designation:

22 (a) gamma-hydroxybutyric acid, also known as gamma-hydroxybutyrate, 4-hydroxybutyrate, 4-
23 hydroxybutanoic acid, sodium oxybate, sodium oxybutyrate, and GHB;

24 (b) mecloqualone;

25 (c) methaqualone; and

26 (d) substituted benzodiazepines, unless specifically excepted, listed in another schedule, in an
27 administrative rule regulating controlled substances, approved for use by the United States food and drug
28 administration, or not used within legitimate and approved medical research, any material, compound, mixture,